Cargando…

Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection

Two mRNA vaccines (BNT162b2 and mRNA-1273) against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) are globally authorized as a two-dose regimen. Understanding the magnitude and duration of protective immune responses is vital to curbing the pandemic. We enrolled 461 high-risk health se...

Descripción completa

Detalles Bibliográficos
Autores principales: Gray, Ashley N., Martin-Blais, Rachel, Tobin, Nicole H., Wang, Yan, Brooker, Sarah L., Li, Fan, Gadoth, Adva, Elliott, Julie, Faure-Kumar, Emmanuelle, Halbrook, Megan, Hofmann, Christian, Kashani, Saman, Kazan, Clayton, Yang, Otto O., Fulcher, Jennifer A., Grovit-Ferbas, Kathie, Rimoin, Anne W., Aldrovandi, Grace M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575273/
https://www.ncbi.nlm.nih.gov/pubmed/34748607
http://dx.doi.org/10.1371/journal.pone.0259703
_version_ 1784595644714844160
author Gray, Ashley N.
Martin-Blais, Rachel
Tobin, Nicole H.
Wang, Yan
Brooker, Sarah L.
Li, Fan
Gadoth, Adva
Elliott, Julie
Faure-Kumar, Emmanuelle
Halbrook, Megan
Hofmann, Christian
Kashani, Saman
Kazan, Clayton
Yang, Otto O.
Fulcher, Jennifer A.
Grovit-Ferbas, Kathie
Rimoin, Anne W.
Aldrovandi, Grace M.
author_facet Gray, Ashley N.
Martin-Blais, Rachel
Tobin, Nicole H.
Wang, Yan
Brooker, Sarah L.
Li, Fan
Gadoth, Adva
Elliott, Julie
Faure-Kumar, Emmanuelle
Halbrook, Megan
Hofmann, Christian
Kashani, Saman
Kazan, Clayton
Yang, Otto O.
Fulcher, Jennifer A.
Grovit-Ferbas, Kathie
Rimoin, Anne W.
Aldrovandi, Grace M.
author_sort Gray, Ashley N.
collection PubMed
description Two mRNA vaccines (BNT162b2 and mRNA-1273) against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) are globally authorized as a two-dose regimen. Understanding the magnitude and duration of protective immune responses is vital to curbing the pandemic. We enrolled 461 high-risk health services workers at the University of California, Los Angeles (UCLA) and first responders in the Los Angeles County Fire Department (LACoFD) to assess the humoral responses in previously infected (PI) and infection naïve (NPI) individuals to mRNA-based vaccines (BNT162b2/Pfizer- BioNTech or mRNA-1273/Moderna). A chemiluminescent microparticle immunoassay was used to detect antibodies against SARS-CoV-2 Spike in vaccinees prior to (n = 21) and following each vaccine dose (n = 246 following dose 1 and n = 315 following dose 2), and at days 31–60 (n = 110) and 61–90 (n = 190) following completion of the 2-dose series. Both vaccines induced robust antibody responses in all immunocompetent individuals. Previously infected individuals achieved higher median peak titers (p = 0.002) and had a slower rate of decay (p = 0.047) than infection-naïve individuals. mRNA-1273 vaccinated infection-naïve individuals demonstrated modestly higher titers following each dose (p = 0.005 and p = 0.029, respectively) and slower rates of antibody decay (p = 0.003) than those who received BNT162b2. A subset of previously infected individuals (25%) required both doses in order to reach peak antibody titers. The biologic significance of the differences between previously infected individuals and between the mRNA-1273 and BNT162b2 vaccines remains uncertain, but may have important implications for booster strategies.
format Online
Article
Text
id pubmed-8575273
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-85752732021-11-09 Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection Gray, Ashley N. Martin-Blais, Rachel Tobin, Nicole H. Wang, Yan Brooker, Sarah L. Li, Fan Gadoth, Adva Elliott, Julie Faure-Kumar, Emmanuelle Halbrook, Megan Hofmann, Christian Kashani, Saman Kazan, Clayton Yang, Otto O. Fulcher, Jennifer A. Grovit-Ferbas, Kathie Rimoin, Anne W. Aldrovandi, Grace M. PLoS One Research Article Two mRNA vaccines (BNT162b2 and mRNA-1273) against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) are globally authorized as a two-dose regimen. Understanding the magnitude and duration of protective immune responses is vital to curbing the pandemic. We enrolled 461 high-risk health services workers at the University of California, Los Angeles (UCLA) and first responders in the Los Angeles County Fire Department (LACoFD) to assess the humoral responses in previously infected (PI) and infection naïve (NPI) individuals to mRNA-based vaccines (BNT162b2/Pfizer- BioNTech or mRNA-1273/Moderna). A chemiluminescent microparticle immunoassay was used to detect antibodies against SARS-CoV-2 Spike in vaccinees prior to (n = 21) and following each vaccine dose (n = 246 following dose 1 and n = 315 following dose 2), and at days 31–60 (n = 110) and 61–90 (n = 190) following completion of the 2-dose series. Both vaccines induced robust antibody responses in all immunocompetent individuals. Previously infected individuals achieved higher median peak titers (p = 0.002) and had a slower rate of decay (p = 0.047) than infection-naïve individuals. mRNA-1273 vaccinated infection-naïve individuals demonstrated modestly higher titers following each dose (p = 0.005 and p = 0.029, respectively) and slower rates of antibody decay (p = 0.003) than those who received BNT162b2. A subset of previously infected individuals (25%) required both doses in order to reach peak antibody titers. The biologic significance of the differences between previously infected individuals and between the mRNA-1273 and BNT162b2 vaccines remains uncertain, but may have important implications for booster strategies. Public Library of Science 2021-11-08 /pmc/articles/PMC8575273/ /pubmed/34748607 http://dx.doi.org/10.1371/journal.pone.0259703 Text en © 2021 Gray et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Gray, Ashley N.
Martin-Blais, Rachel
Tobin, Nicole H.
Wang, Yan
Brooker, Sarah L.
Li, Fan
Gadoth, Adva
Elliott, Julie
Faure-Kumar, Emmanuelle
Halbrook, Megan
Hofmann, Christian
Kashani, Saman
Kazan, Clayton
Yang, Otto O.
Fulcher, Jennifer A.
Grovit-Ferbas, Kathie
Rimoin, Anne W.
Aldrovandi, Grace M.
Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection
title Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection
title_full Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection
title_fullStr Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection
title_full_unstemmed Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection
title_short Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection
title_sort humoral responses to sars-cov-2 mrna vaccines: role of past infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575273/
https://www.ncbi.nlm.nih.gov/pubmed/34748607
http://dx.doi.org/10.1371/journal.pone.0259703
work_keys_str_mv AT grayashleyn humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT martinblaisrachel humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT tobinnicoleh humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT wangyan humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT brookersarahl humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT lifan humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT gadothadva humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT elliottjulie humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT faurekumaremmanuelle humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT halbrookmegan humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT hofmannchristian humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT kashanisaman humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT kazanclayton humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT yangottoo humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT fulcherjennifera humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT grovitferbaskathie humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT rimoinannew humoralresponsestosarscov2mrnavaccinesroleofpastinfection
AT aldrovandigracem humoralresponsestosarscov2mrnavaccinesroleofpastinfection